1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm [Yahoo! Finance]
Artivion, Inc. (AORT)
Company Research
Source: Yahoo! Finance
A business making money today isn't necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here is one profitable company that balances growth and profitability and two best left off your watchlist. Two Stocks to Sell: Artivion (AORT) Trailing 12-Month GAAP Operating Margin: 7.6% Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE:AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. Why Are We Hesitant About AORT? Smaller revenue base of $441.3 million means it hasn't achieved the economies of scale that some industry juggernauts enjoy Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of -0.6% for the last five years Low returns on capital reflect management's struggle to allocate funds effectively At $35.43
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- How The Investment Story Is Shifting For Artivion (AORT) After Recent Analyst And FDA Updates [Yahoo! Finance]Yahoo! Finance
- 1 Stock Under $50 to Own for Decades and 2 We Avoid [Yahoo! Finance]Yahoo! Finance
- Artivion (AORT) was upgraded by LADENBURG THALM/SH SH from "neutral" to "buy". They now have a $42.00 price target on the stock.MarketBeat
- Artivion Secures FDA Approval for NEXUS Aortic Arch System [Yahoo! Finance]Yahoo! Finance
- Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know [Yahoo! Finance]Yahoo! Finance
AORT
Earnings
- 2/12/26 - Beat
AORT
Sec Filings
- 4/1/26 - Form ARS
- 4/1/26 - Form DEFA14A
- 4/1/26 - Form DEF
- AORT's page on the SEC website